The new antifungal azoles: fluconazole and itraconazole

Abstract

The armamentarium against severe mycoses was recently enriched with the triazole antifungals. The ease of administration and the favorable toxicity profile, coupled with increasing evidence of therapeutic efficacy against a broad spectrum of fungal organisms, make fluconazole and itraconazole valuable agents in the management of fungal infections. Fluconazole prevents superficial and invasive mycoses in patients at risk, and recent studies have proved its efficacy in the treatment of candidiasis and cryptococcosis. Itraconazole has activity against Aspergillus and is useful in suppressing disseminated histoplasmosis in patients with AIDS. The positive impact of the new triazoles in the outcome of patients with, or at risk of, fungal infections is clearly shown from available data. Results of ongoing and future clinical trials will better determine their indications and their optimal dose schedules